《物理与工程》现已启动“量子战团”专题征稿。欢迎投递量子物理理论、量子计算技术、量子通信、量子精密测量等领域的原创内容（包括学术研究、科普文章、前沿评述，但不限于上述范围）。投稿稿件将通过绿色通道优先送审，录用文章网络首发后择其中合适的内容在微信公众号、人民号、澎湃号等全网推送。投稿网址：http://gkwl.cbpt.cnki.net

人工智能生物技术公司 Auransa 和基于量子的药物设计公司 Polaris Quantum Biotech （以下简称Polarisqb）宣布在乳腺癌靶点方面取得重要进展。

利用Auransa 和 Polarisqb两家公司的人工智能驱动生物学和基于量子的化学相结合的技术，他们正在研究一种易感途径，该途径可能可以更好地靶向三阴性乳腺肿瘤并改善患者预后。

根据公司报告，使用 Auransa 的SMarTR 引擎和人类疾病数据，他们已经确定了一种预计相关的生物途径，在这一途径中，两家公司预测了两个有希望的蛋白质靶点。

使用 Polarisqb 的 Tachyon 平台，这些公司设计了一个虚拟化学空间，其中包含针对每个蛋白质靶标的数十亿个分子，并在其中搜索新的分子结构。为每个目标确定了几组线索，并将在实验室进行进一步测试。

凭借 SMarTR 引擎独特的 AI 方法，利用异构人类数据和 Tachyon 在大型化学空间中基于量子计算的高精度和快速搜索技术对复杂生物学进行反卷积。

Auransa 的首席执行官Pek Lum 博士说：“我们对迄今为止取得的进展感到非常满意，在很短的时间内，我们能够从疾病组织的分子数据和预测目标到确定一组有希望的线索，突出了两个团队的技能、意志和协作性质。”

Polarisqb 首席执行官 Shahar Keinan 博士表示：“我们很高兴与 Auransa 合作解决制药行业一直以来未满足的需求，并为两个团队在如此短的时间内取得的成就感到自豪。这类项目正在展示两家公司技术的实力和协同作用，我们期待继续致力于这些具有挑战性的目标，并以更快和更大规模的方式提供解决方案。”

以下为原文内容：

Auransa, Inc.,an AI biotech and Polaris Quantum Biotech (Polarisqb), a quantum based drug design company, announce progress on important breast cancer target.

PALO ALTO, CA, DURHAM, NC, USA, August 9, 2022 /EINPresswire.com/ -- Auransa, Inc., an artificial intelligence (AI) company developing precision medicines in areas of unmet medical needs, and Polaris Quantum Biotech (Polarisqb), a quantum computing-based drug design company, announced exciting progress in a joint project to tackle triple-negative breast cancer. Triple-negative breast cancer is an aggressive cancer, accounting for about 15% of breast cancers. It has fewer treatment options and tends to have a worse outcome than other breast cancers. Using the companies’ combined technology of AI-driven biology and quantum-based chemistry, they are working on a susceptible pathway that might allow better targeting of triple-negative breast tumors and improved patient outcomes.

The companies report that using Auransa’s SMarTR Engine and human disease data, they have identified a biological pathway that is predicted to be relevant and hence, likely to be important for patient outcomes. Within this pathway, the companies predicted two promising protein targets. Using Polarisqb’s Tachyon platform, the companies have designed a virtual chemical space containing billions of molecules for each protein target, and searched it for novel molecular structures. Several sets of leads were identified for each target and will be further tested in the laboratory. With the SMarTR Engine‘s unique AI approach to deconvolute complex biology using heterogeneous human data and Tachyon's highly accurate and rapid quantum computing-based search technology in large chemical space, the collaboration was able to progress with unprecedented speed and scale, taking only six months from data collection to molecular leads identified for two different pharmaceutical targets.

“We are very pleased with the progress we have made so far and are looking forward to bringing some of these unique molecules that were identified by the Tachyon platform to the wet bench. In a short amount of time, we were able to go from molecular data of disease tissues and predicting targets to identifying sets of promising leads, highlighting the skill, will, and the collaborative nature of the two teams” said Pek Lum, Ph.D., CEO of Auransa.

Shahar Keinan, Ph.D., CEO of Polarisqb, said "We are excited to collaborate with Auransa on such an unmet need in the pharmaceutical industry and are proud of what the two teams have achieved in such a short time. These kinds of projects are showing the strength and synergy of both companies' technologies, and we are looking forward to continuing to work on challenging targets such as these, and to bringing solutions both faster and at scale”.

Auransa is artificial intelligence (AI)-driven pharmaceutical company developing precision medicines in areas of significant unmet need. They are working to redefine medicine, combining a sophisticated, proprietary, and predictive computational platform with traditional pharmaceutical experience. The company's SMarTR™ Engine has proprietary machine learning, advanced analytics, and mathematics in an AI framework to generate insights from molecular data for a deep understanding of disease biology and patient subtypes. Auransa has successfully generated a broad pipeline of drug candidates focusing on cancer and cancer care. Learn more: www.auransa.com.

Polaris Quantum Biotech, a leader in Quantum Computing for drug discovery, has created the first drug discovery platform built on a Quantum Computer. Founded in 2020 by Shahar Keinan, CEO, and Bill Shipman, CTO, Polarisqb uses the latest quantum and cloud computing, artificial intelligence, and machine learning to process, evaluate and identify drug lead molecules 10,000 times faster than alternative solutions. With real-time adaptability, Polarisqb plans to produce up to 100 drug leads annually. The resulting high-quality drug lead will be taken to synthesis, testing, and licensed to pharmaceutical partners for further development within months, rather than years. Additional information is available at www.Polarisqb.com

原文网址：

[1]https://www.einpresswire.com/article/585048367/polarisqb-and-auransa-announce-promising-results-for-triple-negative-breast-cancer-using-quantum-computing-and-ai

本文内容综合量子客、EIN Presswire网站等。